[Highlights 2007 in hospital-based internal medicine: the point of view from the chief residents].
In 2007, several international studies brought useful information for the daily work of internists in hospital settings. This summary is of course subjective but reflects the interests and questions of the chief residents of the Department of internal medicine who wrote this article like an original trip in medical literature. This trip will allow you to review some aspects of important fields such as heart failure, diabetes, endocarditis, COPD, and quality of care. Besides the growing diversity of the fields covered by internal medicine, these various topics underline also the uncertainty internists have to face in a practice directed towards evidence.
Deriaz-Chessex
S
S
Service de médecine interne, CHUV, Lausanne. Sandra.Deriaz@chuv.ch
Carron
P
P
Gachoud
D
D
Fournier
Y
Y
Donzé
J
J
Monti
M
M
Achtari Jeanneret
L
L
Rossier
A
A
Moix
P A
PA
Barras-Moret
A C
AC
Wilson
P
P
D000058:Accidental Falls / Q000517:prevention & control; D000368:Aged; D000420:Albuterol / Q000031:analogs & derivatives / Q000627:therapeutic use; D000740:Anemia / Q000188:drug therapy; D000925:Anticoagulants / Q000627:therapeutic use; D065092:Antidiuretic Hormone Receptor Antagonists; D001281:Atrial Fibrillation / Q000209:etiology; D001291:Attitude of Health Personnel; D001552:Benzazepines / Q000627:therapeutic use; D029481:Bronchitis, Chronic / Q000188:drug therapy; D001993:Bronchodilator Agents / Q000627:therapeutic use; D002304:Cardiac Pacing, Artificial / Q000379:methods; D003920:Diabetes Mellitus / Q000209:etiology; D004697:Endocarditis, Bacterial / Q000517:prevention & control; D004921:Erythropoietin / Q000627:therapeutic use; D006333:Heart Failure / Q000188:drug therapy; D006493:Heparin / Q000627:therapeutic use; D006801:Humans; D007388:Internal Medicine; D007400:Interprofessional Relations; D008505:Medical Staff, Hospital; D009203:Myocardial Infarction / Q000150:complications / Q000188:drug therapy; D011994:Recombinant Proteins; D012308:Risk Management; D000077154:Rosiglitazone; D000068299:Salmeterol Xinafoate; D045162:Thiazolidinediones / Q000627:therapeutic use; D013923:Thromboembolism / Q000517:prevention & control; D000077602:Tolvaptan; D014665:Vasodilator Agents / Q000627:therapeutic use; D018487:Ventricular Dysfunction, Left / Q000628:therapy; D016526:Workload
D000925:Anticoagulants; D065092:Antidiuretic Hormone Receptor Antagonists; D001552:Benzazepines; D001993:Bronchodilator Agents; D011994:Recombinant Proteins; D045162:Thiazolidinediones; D014665:Vasodilator Agents; D000077154:Rosiglitazone; D004921:Erythropoietin; D000077602:Tolvaptan; D000068299:Salmeterol Xinafoate; D006493:Heparin; D000420:Albuterol